VIGILVESTLibrary
← Library

VERTEX PHARMACEUTICALS INC / MA

VRTX
SEC CIK 875320Price charts ↗
Writing the earnings story…

Financials

Revenue+7.8% YoY
$2.99B
Sep '23Mar '24Jun '24Sep '24Mar '25Jun '25Sep '25Mar '26
Net Income+59.6% YoY
$1.03B
Sep '23Mar '24Jun '24Sep '24Mar '25Jun '25Sep '25Mar '26
EPS (diluted)+61.4% YoY
$4.02
Sep '23Mar '24Jun '24Sep '24Mar '25Jun '25Sep '25Mar '26
Gross Margin
Sep '23Mar '24Jun '24Sep '24Mar '25Jun '25Sep '25Mar '26
Quarter endingRevenueNet incomeEPS
Mar 2026$2.99B$1.03B$4.02
Sep 2025$3.08B$1.08B$4.2
Jun 2025$2.96B$1.03B$3.99
Mar 2025$2.77B$646.3M$2.49
Sep 2024$2.77B$1.05B$4.01
Jun 2024$2.65B-$3.59B-$13.92
Mar 2024$2.69B$1.10B$4.21
Sep 2023$2.48B$1.04B$3.97

Annual revenue

FY21FY22FY23FY24FY25

Source filings

Download the original reports from the SEC. A 10-Q is the quarterly update; a 10-K is the detailed annual report.

Glossary

Revenue
Net income
EPS
Gross margin
Net margin
Fiscal year

Hover any underlined term for its definition.